Scholar Rock Holding Corporatio (SRRK) concentration risks

The company's disclosed concentration profile is defined by two high-share exposures that together capture the primary risk dimensions of a late-stage clinical-stage biopharmaceutical company: pipeline concentration and manufacturing dependency. The pipeline is centered on apitegromab, a program that reported positive Phase 3 SAPPHIRE study data in October 2024 evaluating it in children and adults with SMA. By disclosed size this is a high-share, mixed-character exposure — structural in that SMA is the company's deliberate therapeutic focus, but mixed because the program has not yet received commercial approval and remains subject to regulatory review. The manufacturing dependency is equally high-share: the company received a Complete Response Letter (CRL) from the FDA citing observations identified during an inspection of a third-party fill-finish facility. This regulatory action directly links the program's path to approval to the operational performance of a single external manufacturer. The dependency character of this exposure is significant — the company does not control the facility, and remediation timelines are set by both the manufacturer and the FDA. An unresolved manufacturing issue at this single site could delay or block commercialization of the company's lead asset. The two exposures are tightly coupled: the entire enterprise value thesis rests on a single program, and the near-term realization of that thesis depends on resolving a third-party manufacturing deficiency. This compounding structure — one asset, one manufacturer — represents the concentrated risk profile disclosed.

For the engine’s reasoning on SRRK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.